Comparison of clinical efficacy of intravitreal injection of Conbercept and Aflibercept in the treatment of wet age-related macular degeneration
10.3980/j.issn.1672-5123.2023.4.26
- VernacularTitle:玻璃体腔注射康柏西普与阿柏西普治疗湿性年龄相关性黄斑变性的疗效比较
- Author:
Ping-Sun YANG
1
;
Zhen-Zhen ZHU
1
;
Yi-Fan LIU
1
Author Information
1. Department of Ophthalmology, Hangzhou Xiaoshan Hospital of Traditional Chinese Medicine, Hangzhou 311200, Zhejiang Province, China
- Publication Type:Journal Article
- Keywords:
vitreous infusion;
recombinant human endostatin;
receptor fusion proteins;
wet age-related macular degeneration;
Conbercept;
Aflibercept
- From:
International Eye Science
2023;23(4):665-667
- CountryChina
- Language:Chinese
-
Abstract:
AIM: To compare the clinical efficacy of conbercept and aflibercept in the treatment of wet age-related macular degeneration(wARMD)based on 4 consecutive intravitreal injections.METHODS: The clinical data of 108 patients(108 eyes)who were diagnosed as wARMD and treated with intravitreal injection at our hospital from January 2019 to January 2021 were retrospectively analyzed. They were divided into conbercept group(54 cases, 54 eyes)and aflibercept group(54 cases, 54 eyes)according to the different injectable drugs. All patients received intravitreal injection once a month, with four consecutive injections. Follow up for 12mo to observe best corrected visual acuity(BCVA), central macular thickness(CMT), complications and recurrence before and after injection.RESULTS: BCVA and CMT of patients in the two groups at 1, 2, 5 and 8mo after injection had no between-group differences(P>0.05), but both were significantly improved compared with those before injection(P<0.05). By the end of follow-up, conjunctival hemorrhage occurred in 2 eyes of the conbercept group at the early stage, and increased intraocular pressure and conjunctival hemorrhage occurred respectively in 2 eyes of the aflibercept group. There were no serious complications related to drug injection such as retinal detachment, complicated cataract, endophthalmitis and retinal pigment epithelial tear in the two groups, and there was no difference in the recurrence rate between the two groups(7% vs. 6%, P=1.000).CONCLUSION: On the basis of continuous 4 times of intravitreal injection, both conbercept and aflibercept are safe and effective in the treatment of wARMD, and the efficacy is even.
